Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer

LONDON and SEATTLE, Wash.—Tenpoint Therapeutics, Ltd., a global, clinical-stage biotechnology company focused on developing treatments to rejuvenate vision in the aging eye, has announced the appointment of Melissa Epperly as chief financial officer (CFO), effective immediately. In this role, Epperly will oversee Tenpoint’s financial strategy, capital markets activities, and operational finance functions as the company prepares for the potential U.S. launch of Brimochol PF, its lead candidate for the treatment of presbyopia, the announcement said.